Scientific Survey
The European Society of Cardiology (ESC) has issued guidelines recommending the use of angiotensin receptor-neprilysin inhibitor (ARNI) therapy for better clinical outcomes in heart failure patients. ARNI is a combination drug that consists of sacubitril and valsartan. The guidelines emphasize that ARNI therapy should be considered a preferred treatment option in patients with heart failure and reduced ejection fraction (HFrEF). It is worth noting that ARNI therapy may not be suitable for all heart failure patients, and individual patient characteristics and considerations should be taken into account when making treatment decisions. The questionnaire aims to gather valuable insights from healthcare professionals regarding the recent guidelines recommendation on the simultaneous initiation of guideline-directed medical therapy (GDMT) in heart failure patients. The questionnaire covers various aspects related to GDMT implementation, including barriers faced, preferred therapies, comorbidities, interventions to overcome challenges, and tools used in daily clinical practice. Overall, it is aimed at gathering insights into the clinical experience regarding the benefits of using ARNI in practice, their feedback, and observed outcomes from this therapy.
Objective of the Survey:
1. To provide participants with in-depth clinical insights and treatment options available in the management of heart failure.
2. To understand evidence-based practices for GDMT initiation and sequencing in Indian patients.
3. To understand the barriers and challenges faced in real-world practice when implementing GDMT for heart failure patients.
4. Further identifying strategies and interventions to overcome the underutilization of GDMT in heart failure management.
Target Audience: Cardiologist / Consultant Physician Diabetologist / Endocrinologist / CVTS